ArticleMolecular biology reports2026
CYP24A1 rs1570669 and rs2762934 polymorphisms and bladder cancer susceptibility: a Turkish case-control study.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundBladder cancer (BC) is one of the most common malignant tumours of the urinary system and represents an important public health problem. Single nucleotide polymorphisms (SNPs) are common human genetic variations and may affect cancer risk by altering various genetic processes such as vitamin D metabolism and tumour suppression. CYP24A1 rs1570669 and rs2762934 polymorphisms may be relevant to cancer biology through their potential effects on the degradation of active vitamin D metabolites. These polymorphisms have been associated with the risk of urinary cancer, including BC, in an Asian population. To the best of our knowledge, the impact of CYP24A1 rs2762934 and rs1570669 variants on BC susceptibility has not yet been investigated in any Caucasian cohort. Consequently, this study represents the first attempt to evaluate their associations with BC risk within a Turkish population. METHODS AND
resultsThe present study investigated CYP24A1 gene polymorphisms in 152 BC patients and 178 healthy controls using a TaqMan allelic discrimination assay with real-time PCR (qPCR). Neither polymorphism was significantly associated with BC risk, although the A alleles of both variants showed a non-significant trend towards increased odds of BC. Additionally, both groups differed significantly regarding age, BMI, and smoking status, but not regarding other characteristics, such as vitamin D levels.
conclusionsThe CYP24A1 rs2762934 and rs1570669 polymorphisms were not significantly associated with BC susceptibility in this Turkish cohort. Despite this, the A alleles of both variants showed a non-significant trend toward increased odds of BC, which may warrant further investigation in larger cohorts.
Indexed as
Identifiers
42859272What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.